Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Aztreonam Lysine for Prevention of Gram Negative Pneumonia in Ventilated Patients
NCT03749226Phase 3Terminated
- Sponsor
- Hospital Universitari Joan XXIII de Tarragona
- Start
- Mar 2019
- Primary completion
- Sep 2019
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aztreonam in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Hospital Universitari Joan XXIII de Tarragona. Primary endpoints: Microbiological cure at 5 days and Incidence of Gram-negative Infection-related Ventilator-Associated Complications. Started Mar 2019; status: terminated.
02
Drugs
aztreonam
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03749226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749226.